Endogenous TNF induction therapy using rTNF-SAM2 in patients with pulmonary metastases from colorectal cancer

Anticancer Research

Volumn 18, Issue 5 D, 1998, Pages 3931-3936

  Yamasaki, Koichi ^a   Hasegawa, Shyuzo ^a   Futami, Kitaro ^a   Arima, Sumitaka ^a  

^a Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Colorectal cancer; EET therapy; Pulmonary metastases; rTNF SAM2; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; FEMALE; FEVER; HEADACHE; HEMATURIA; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; NAUSEA; PRIORITY JOURNAL; RIGOR; THROMBOCYTOPENIA; TUMOR NECROSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNITY, CELLULAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031743979     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Galandick S, Wieand HS, Moertel CG et al: Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 174: 27-32, 1992.
2. Welch JP, Donaldoson GA. Detection and treatment of recurrent cancer of the colon and rectum. Am J Surg 135: 507-511, 1978.
3. Poon MA, OConnel MJ, Wieand HS et al: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991.
4. Pentecost MJ: Transcatheter treatment of hepatic metastases. Am J Roentgenol 160: 1171-1175, 1993.
5. De Takats PG, Kerr DJ, Poole CJ, et al: Hepatic arterial chemotherapy for metastatic colorectal carcinoma(review). Br J Cancer 69: 372-378, 1994.
6. Benotti P and Steele G: Pattern of recurrent colorectal cancer and recovery surgery. Cancer 70: 1409-1413, 1992.
7. Ballantyne GH and Quin J: Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 71: 4252-66, 1993.
8. Que FG and Nagorney DM. Resection of 'recurrent' colorectal metastases to the liver. Br J Surg 81: 255-258, 1994.
9. Girard P, Ducreux M, Baldeyrou P, et al: Surgery for lung metastases from colorectal cancer : Analysis of prognostic factors. J Clin Oncol 14: 2047-2053, 1996.
10. Baron O, Amini M, Duveau D, et al: Surgical resection of pulmonary metastases from colorectal carcinoma. Eur J Cardio-thorac Surg 10: 347-351, 1996.
11. Yano T, Fukuyama Y, Yokoyama H, et al: Failure in resection of multiple pulmonary metastases from colorectal cancer. J Am Coll Surg 185: 120-122, 1997.
12. Windschitl H, Scott M, Schutt A, et al: Randomized phase II studies in advanced colorectal carcinoma: a north central cancer treatment group study. Cancer Threat Res 67: 1001-1008, 1983.
13. Asher A, Mule JJ, Reichrt M, et al: Studies on the Anti-tumor Efficacy of systemically administrated Recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-974, 1987.
14. Dealtry GB, Naylor MS, Fiers WB et al: DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ. Eur J Immunol 17: 689-693, 1987.
15. Watanabe N, Niitu Y, Umeno H, et al: Toxic effect of TNF on tumor vasculature in mice. Cancer Res 49: 2179-2183, 1988.
16. Manusama ER, Durante NMC, Marquet RL, et al: Ischemia promotes the antitumor effect of tumor necrosis factor alpha(TNFα) in isolated limb perfusion in the rat. Reg Cancer Treat 7: 155-159, 1994.
17. Goto S, Suma Y, Noguchi K et al: Augmentation of specific tumor killing activity by tumor-infiltrating lymphocytes (TIL) in the presence of TNF-SAM2. Cancer Biother 10: 37-44, 1995.
18. Kimura K, Taguchi I, Urushizaki R, et al: Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20: 223-229, 1987.
19. Blick MB, Sherwin SA, Rosenblum M, et al: A phase I trial of recombinant human tumor necrosis factor in cancer patients. Cancer Res 47: 2986-2989, 1987.
20. Chapman PB, Lester TJ, Casper ES, et al: Clinical pharmacology of recombinant human necrosis factor in patients with advanced cancer. J Clin Oncol 5: 1942-1951, 1987.
21. Feinberg B, Kurzrock R, Talpaz M, et al: A phase I trial of intravenously administrated recombinant tumor necrosis alpha in cancer patients. J Clin Oncol 6: 1328-1334, 1988.
22. Sherman ML, Springgs DR, Arthur KA, et al: Recombinant human tumor necrosis factor administrated as a five-day continuous infusion in cancer patients. J Clin Oncol 6: 344-350, 1988.
23. Creagan ET, Kovach JS, Moetel CG, et al: A phase I trial of recombinant human tumor necrosis factor. Cancer 62: 2467-2471, 1988.
24. Kemeny N, Childs B, Larchian W, et al: A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66: 659-663, 1990.
25. Gatanaga T, Noguchi K, Tanabe Y, Soma G-I, et al: Antitumor effect of systemic administration of novel recombinant tumor necrosis factor(γTNF-S) with less toxicity than conventional rTNF-α in vivo. J Biol Resp Modif 8: 278-286, 1989.
26. Soma G-I, Kitahara N, Tsuji Y, Kato M, et al: Improvement of cytotoxicity of tumor necrosis factor(TNF) by increase in basicity of its N-terminal region. Biochem Bio-phys Res Commun 148: 629-635, 1987.
27. Soma G-I, Tsuji Y, Tanabe M, et al: Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells. J Biol Response Mod 7: 587-595, 1988.
28. Mizuno D, Soma G-I: Endogenous and exogenous TNF therapy(EET therapy) : conceptual and experimental grounds. Ann Inst Pasteur Immunol 139: 282-285, 1988.
29. Inagawa H, Oshima H, Soma G-I., et al: TNF induces endogenous TNF in vivo: the basis of EET therapy as a combination of rTNF together with endogenous TNF. J Biol Response Mod 7: 596-607, 1988.
30. Nishizawa T, Okutomi T, Inagawa H, et al: Intratumoral tumor necrosis factor induction in tumor-bearing mice by exogenous / endogenous tumor necrosis factor therapy as compared with systemic administration of various biologic response modifiers. Mol Biother 3: 224-230, 1991.
31. Takagi K, Fujiyoshi T, Takano M, et al: Endogenous and exogenous TNF therapy(EET therapy) to metastatic lesions in liver and local recurrent lesions of colorectal carcinoma. Immunobiology 175: 57-58, 1987.
32. Soma G-I, Mizuno D, Exogenous and endogenous tumor necrosis factor therapy. Biotechnology Research Center, Cancer Surv 8: 837-852, 1989.
33. Izumi IT, Yazaki T, Waku M, and Soma G-I, Immunichemotherapy for murine bladder tumor with a new human recombinant tumor necrosis factor (rTNF-S), VP-16 and ahyperthermia. J Urol 142: 386-389, 1989.
34. Manda T, Nishigaki F, Mukumoto S, et al: The efficacy of combined treatment with recombinant human tumor necrosis factor-α and 5-fuluorouracil is dependent on development of capillaries in tumor. Eur J Cancer 26: 93-99, 1990.
35. Manusama ER, Nooijen PTGA, Stavast J, et al: Synergistic antitumor effect of recombinant human tumor necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-555, 1996.
36. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979.
37. Kyoto Research Group For Digestive Organ Surgery: A comprehensive multi-institutional study on postoperative adjuvant immunotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Ann Surg 276: 44-54, 1992.
38. Ohwada S, Ogawa T, Izumi M, et al: Effect of 5'-DFUR and OK-432 on cytokines as thymidine phosphorylase in tumor tissue of gastric cancer patients. Ann Cancer Res 17: 2313-2318, 1997.
39. Davey FR, Olson S, Kurec AS, et al: The immunophenotyping of extramedullary myeloid cell tumors in paraffin-embedded tissue sections. Am J Surg Pathol 12: 699-707, 1988.
40. Norton AJ, Ramsay AD, Smith SS, et al: Monoclonal antibody (UCHL-1) that recognizes normal and neoplastic T cells in routinely fixed tissues. J Clin Pathol 39: 399-405, 1986.
41. Eggermont AMM, Koops HS, Lienard D, et al: Isolated limb perfusion with high-dose rumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas : A multicenter trial. J clin Oncol 14: 2653-2665, 1996.
42. Fraker DL, Alexander HR and Thom AK. Use of tumor necrosis factor in isolated hepatic perfusion.Circ Shock 44: 45-50, 1994.
43. Kuppen PJK, Jonger LE, van ge Velde CJH, et al: Liver and tumor tissue concentrations of TNF-α in cancer patients treated with TNF-α and melphalan by isolated liver perfusion. Br J Cancer 75: 1498-1500, 1997.
44. Wong GHW and Goeddel DV: Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242: 941-944, 1988.
45. Himeno T, Watanabe N, Yamauchi N, et al: Induction of synthesis of manganous superoxide dismutase in L-M(pNTnF) cells carrying inducible TNF gene. Int J Cancer 50: 458-462, 1992.